Terms ending in 2035
Every in-force patent on Mesoblast, Inc.'s record whose computed term ends in 2035, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,400,218 | Improved Stem Cell Composition In force · High confidence | Mesoblast International SARL | In force | High confidence | |
| US 11,312,941 | Stem Cell Composition In force · High confidence | Mesoblast International SARL | In force | High confidence | |
| US 12,616,722 | Treatment of Immune Disorders In force · High confidence | Mesoblast International SARL | In force | High confidence | |
| US 10,624,930 | Treatment of Immune Disorders In force · High confidence | Mesoblast International SARL | In force | High confidence | |
| US 12,257,270 | Treatment of Immune Disorders In force · Low confidence | Mesoblast International SARL | In force | Low confidence | |
| US 11,491,188 | Prevention of Progressive Heart Failure In force · High confidence | Mesoblast International SARL | In force | High confidence | |
| US 11,712,452 | Method for Treating Heart Failure In force · High confidence | Mesoblast International SARL | In force | High confidence | |
| US 12,115,194 | Prevention of Progressive Heart Failure In force · Low confidence | Mesoblast International SARL | In force | Low confidence | |
| US 12,303,536 | Method for Treating Heart Failure In force · High confidence | Mesoblast International SARL | In force | High confidence |
9 of 9 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.